Article
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).
Journal of medicinal chemistry - 10 May 2018
Wagner Rolf, Randolph John T, Patel Sachin V, Nelson Lissa, Matulenko Mark A, Keddy Ryan, Pratt John K, Liu Dachun, Krueger A Chris, Donner Pamela L, Hutchinson Douglas K, Flentge Charles, Betebenner David, Rockway Todd, Maring Clarence J, Ng Teresa I, Krishnan Preethi, Pilot-Matias Tami, Collins Christine, Panchal Neeta, Reisch Thomas, Dekhtyar Tatyana, Mondal Rubina, Stolarik DeAnne F, Gao Yi, Gao Wenqing, Beno David A, Kati Warren M
Abstract excerpt
Curative interferon and ribavirin sparing treatments for hepatitis C virus (HCV)-infected patients require a combination of mechanistically orthogonal direct acting antivirals. A shared component of these treatments is usually an HCV NS5A inhibitor. First generation FDA approved treatments, including the component NS5A inhibitors, do not exhibit equivalent efficacy against HCV virus genotypes 1-6. In particular,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.